The United States Patent and Trademark Office (USPTO) has issued patent US12582701B2 to Simcha IL-18, Inc. This patent covers novel stabilized Interleukin-18 (IL-18) polypeptides and methods for their therapeutic and non-therapeutic applications. The invention specifically addresses the challenge of maintaining IL-18 signaling activity in the presence of inhibitory molecules like IL-18BP, offering potential advancements in treating various conditions.

This patent grant signifies the protection of intellectual property related to IL-18 variants. While not imposing direct compliance obligations on other entities, it is relevant for pharmaceutical and biotechnology companies operating in the immunology and therapeutic protein space. Companies developing or researching IL-18 therapies should be aware of this patent to ensure their activities do not infringe upon the granted claims, particularly concerning the specific stabilized IL-18 compositions and methods of use.